Clinical Trial: Topical Rapamycin for Fibrofolliculomas

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome

Brief Summary: The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones. Secondary we evaluate rapamycin safety, formula acceptance and patient satisfaction.

Detailed Summary:
Sponsor: Maastricht University Medical Center

Current Primary Outcome: Significant regression of lesions (reduction of fibrofolliculoma size and count) in the treated area. [ Time Frame: 3 and 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Side effects [ Time Frame: 3 and 6 months ]

Original Secondary Outcome: Same as current

Information By: Maastricht University Medical Center

Dates:
Date Received: June 25, 2009
Date Started: January 2010
Date Completion:
Last Updated: March 7, 2012
Last Verified: March 2012